a comparison between pegylated interferon alpha-2a and standard interferon in combination with ribavirin in treating patients with bleeding disorders and chronic hepatitis c
نویسندگان
چکیده
background: patients with bleeding disorders are frequently infected with hepatitis c virus (hcv). there are few reports on the effect of standard interferon in these patients and no published report on pegylated interferon. the aim of this study was to compare pegylated interferon alpha-2a and standard interferon alpha with ribavirin in patients with bleeding disorders and chronic hcv infection. materials and methods: consecutive patients referring to a specialized clinic in tehran were included in the study. the first 37 patients received pegylated interferon (pegasys, hoffmann-la roche inc., basel, switzerland), 180 î¼g weekly and the next 38 patients received standard interferon, 3 million units 3 times a week. both groups also received ribavirin 800 mg daily. patients were treated for 48 weeks and were followed for 24 weeks. liver biopsy was not performed due to the potential risks involved in patients with bleeding disorders. results: 34 patients in each group completed the study. the intention-to-treat sustained viral response was 34% and 62% in the standard interferon and pegylated interferon group, respectively (p=0.02). conclusions: pegylated interferon alpha-2a and ribavirin is almost twice as effective as standard interferon and ribavirin in treating hcv infection in patients with bleeding disorders and is an acceptable treatment option even when histologic data is not available.
منابع مشابه
EFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C
Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...
متن کاملIncidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
OBJECTIVES The objective of this study was to determine the incidence of retinopathy in chronic hepatitis C patients treated with Pegylated interferon alpha 2a and Ribavirin. METHODS This descriptive case series study was conducted in Medical Unit II of the Jinnah Hospital Lahore from September 2012 to February 2013. One hundred chronic hepatitis C patients visiting Medical Unit II outpatient...
متن کاملPegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
BACKGROUND Chronic hepatitis C virus (HCV) infection is associated with liver dysfunction and hepatocellular carcinoma. In patients with normal kidney function, treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) frequently leads to eradication of HCV. Treatment in dialysis patients has long been controversial and until recently, the use of RBV was considered to be contra-indicate...
متن کاملThe efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
BACKGROUND/AIMS We aimed to compare viral responses to pegylated interferon 2a plus ribavirin with pegylated interferon alpha 2b plus ribavirin. METHODS Patients with the following characteristics were included: anti HCV(+); normal and/or elevated serum transaminase levels; positive HCV RNA by quantitative PCR; and at least stage 1 fibrosis according to Knodell Scoring System on liver biopsy....
متن کاملInterstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Pulmonary toxicity is a rare but potentially fatal side effect occurring during interferon (IFN) alpha treatment for chronic hepatitis C. We present a 47-year-old woman who had chronic hepatitis C and was treated with pegylated IFN alpha-2b in combination with ribavirin, with a good virological response by week 10 of therapy. Then the patient began to complain of dyspnea on exertion and a dry c...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
گوارشجلد ۱۰، شماره ۲، صفحات ۱۰۸-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023